Roche Holding (RHHB.F) Stock Overview

Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. More details

RHHB.F fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	5/6
Financial Health	4/6
Dividends	5/6

Rewards

Trading at 52.3% below our estimate of its fair value

Earnings are forecast to grow 10.5% per year

Earnings grew by 55.6% over the past year

Pays a reliable dividend of 2.73%

Risk Analysis

Has a high level of debt

RHHB.F Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Unicycive Therapeutics

Looking to be second time lucky with a game-changing new product

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more

US$21.53

67.2% undervalued

stuart_roberts's Fair Value

Profit Margin

20%

Future PE

27x

Price in 2030

US$34.67

Roche Holding AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for Roche Holding
Historical stock prices
Current Share Price	CHF 488.00
52 Week High	CHF 514.08
52 Week Low	CHF 288.90
Beta	0.21
1 Month Change	10.91%
3 Month Change	20.59%
1 Year Change	35.55%
3 Year Change	61.99%
5 Year Change	42.24%
Change since IPO	290.40%

Recent updates

Shareholder Returns

	RHHB.F	US Pharmaceuticals	US Market
7D	1.6%	-1.5%	-1.2%
1Y	35.6%	21.0%	17.6%

Return vs Industry: RHHB.F exceeded the US Pharmaceuticals industry which returned 22.2% over the past year.

Return vs Market: RHHB.F exceeded the US Market which returned 18.2% over the past year.

Price Volatility

Is RHHB.F's price volatile compared to industry and market?
RHHB.F volatility
RHHB.F Average Weekly Movement	7.7%
Pharmaceuticals Industry Average Movement	9.6%
Market Average Movement	6.6%
10% most volatile stocks in US Market	16.1%
10% least volatile stocks in US Market	3.2%

Stable Share Price: RHHB.F has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: RHHB.F's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1896	103,249	Thomas Schinecker	www.roche.com

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions.

Roche Holding AG Fundamentals Summary

How do Roche Holding's earnings and revenue compare to its market cap?
RHHB.F fundamental statistics
Market cap	US$368.23b
Earnings (TTM)	US$16.53b
Revenue (TTM)	US$81.31b

22.2x

P/E Ratio

4.5x

P/S Ratio

Is RHHB.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RHHB.F income statement (TTM)
Revenue	CHF 63.36b
Cost of Revenue	CHF 16.16b
Gross Profit	CHF 47.19b
Other Expenses	CHF 34.31b
Earnings	CHF 12.88b

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

Jul 23, 2026

Earnings per share (EPS)	16.19
Gross Margin	74.49%
Net Profit Margin	20.33%
Debt/Equity Ratio	83.5%

How did RHHB.F perform over the long term?

See historical performance and comparison

Dividends

2.7%

Current Dividend Yield

61%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/03/04 11:01
End of Day Share Price	2026/03/04 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Roche Holding AG is covered by 46 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
John Staszak	Argus Research Company
Gerhard Schwarz	Baader Helvea Equity Research
Emily Field	Barclays

Roche Holding (RHHB.F) Stock Overview

Rewards

Risk Analysis

Looking to be second time lucky with a game-changing new product

Roche Holding AG Competitors

Merck

Johnson & Johnson

Bristol-Myers Squibb

Pfizer

Price History & Performance

Recent News & Updates

FDA Accepts New Drug Application for Roche’s Giredestrant in ESR1-Mutated, Er-Positive Advanced Breast Cancer

Roche Announces the Appointment of Mark Dawson as New Head of Roche Pharma Research and Early Development and Member of the Enlarged Corporate Executive Committee, Effective 1 May 2026

Roche Announces Positive Phase III Results for Gazyva/Gazyvaro in Primary Embarked A Significant Milestone in This Auto Autoimmune Disease

Roche Holding Proposes Dividend

Roche Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living with Obesity

Roche Holding AG to Report Fiscal Year 2025 Results on Jan 29, 2026

Recent updates

FDA Accepts New Drug Application for Roche’s Giredestrant in ESR1-Mutated, Er-Positive Advanced Breast Cancer

Roche Announces the Appointment of Mark Dawson as New Head of Roche Pharma Research and Early Development and Member of the Enlarged Corporate Executive Committee, Effective 1 May 2026

Roche Announces Positive Phase III Results for Gazyva/Gazyvaro in Primary Embarked A Significant Milestone in This Auto Autoimmune Disease

Roche Holding Proposes Dividend

Roche Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living with Obesity

Roche Holding AG to Report Fiscal Year 2025 Results on Jan 29, 2026

Roche Announces U.S. Launch of Next-Generation Cobas 6800/8800 Systems and Software, Enhancing Laboratory Efficiency and Testing Capabilities

Roche Receives FDA Approval for First Diagnostic Tests to Identify HER2-Positive Metastatic Breast Cancer Patients Eligible for ENHERTU

European Commission Approves Gazyva/Gazyvaro for Adults with Active Lupus Nephritis

Roche Presents Lunsumio Data Showing Potential Across Earlier Treatment Lines in Indolent and Aggressive Lymphomas

Roche Receives FDA Clearance with CLIA waiver and CE Mark for its First Point-Of-Care Test for Diagnosing Bordetella Infections, Including Whooping Cough (pertussis)

European Commission Approves Roche's Lunsumio Subcutaneous for Relapsed or Refractory Foothicular Lymphoma

Roche's Giredestrant Becomes the First Oral SerD to Show Superior Invasive Disease-Free Survival in Early Breast Cancer

Roche's Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple Sclerosis

Roche to Present New Data from its Broad and Innovative Haematology Portfolio at ASH 2025

Roche Announces Positive Phase III Data for Roche’s Gazyva/Gazyvaro Show Significant Reduction in Disease Activity for Systemic Lupus Erythematosus

Roche Holding AG (SWX:ROG) completed the acquisition of 89bio, Inc. (NasdaqGM:ETNB) in a tender offer transaction.

Roche Announces Positive Phase III Results for Gazyva/Gazyvaro in Children and Young Adults with Idiopathic Nephrotic Syndrome

Roche Announces Appointment of Nina Schwab-Hautzinger as Head of Group Communications and Member of the Enlarged Corporate Executive Committee, Effective 1 February 2026

Cmedsir Announces the Positive Results of Its Empress Study, Conducted in Collaboration with Roche Farma

FDA Approves Genentech's Gazyva for the Treatment of Lupus Nephritis

Roche’s Phase III evERA Data Showed Giredestrant Significantly Improved Progression-Free Survival in People with ER-Positive Advanced Breast Cancer

Roche Presents New Phase III Pivotal Data for Vamikibart in Uveitic Macular Edema

CHMP Recommends EU Approval of Roche's Gazyva/Gazyvaro for Lupus Nephritis

Roche Receives CE Mark for AI-Based Kidney Klin Risk Algorithm and Launches New Comprehensive Chronic Kidney Disease (CKD) Algorithm Panel

Claudia Süssmuth Dyckerhoff Decides Not to Stand for Re-Election as a Member of the Roche Board of Directors

Roche Announces Primary Results from the TSIX Study Program

Roche Presents New Data for OCREVUS and Fenebrutinib Across Broad Patient Populations at ECTRIMS 2025

Roche S.A. Announces Positive Phase III Results Show Roche's Giredestrant Significantly Improved Pro progression-Free Survival in ER-Positive Advanced Breast Cancer

CHMP Recommends EU Approval of Roche's Subcutaneous Formulation of Lunsumio for People with Relapsed or Refractory Follicular Lymphoma

Roche Achieves First CLIA 'Moderate Complexity' categorization for Ionify®? 25-Hydroxy Vitamin D Total Test

Roche Announces New Data Reinforcing Efficacy and Safety of Vabysmo in Treating nAMD

Roche's First Respiratory Test Powered by TAGS Technology Receives FDA Clearance for SARS-CoV-2, Influenza A, Influenza B and RSV

Roche Announces its New Innovations In-Booth at Association for Diagnostics & Laboratory Medicine Scientific Meeting and Clinical Lab Expo

Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

Genentech Provides Update on FDA Advisory Committee Meeting on Columvi Combination for People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Roche Holding AG, Annual General Meeting, Sep 10, 2025

Roche Present Novel Therapeutic and Diagnostic Advancements in Alzheimer's At Ad/Pd 2025

Roche Holding AG Provides Update on Phase III Ocrevus High Dose Study in People with Relapsing Multiple Sclerosis

Roche Holding AG Approves Dividend

Roche Announces Management Changes

Roche Holding AG to Present New Data At the Muscular Dystrophy Association Conference from 16-19 March, 2025

Roche Announces CHMP Recommends EU Approval of Roche’s Columvi Combination for People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Roche Unveils New Class of Next-Generation Sequencing with Its Novel Sequencing by Expansion Technology

Roche Elecsys sFlt-1/PlGF Ratio for Preeclampsia Receives FDA 510(K) Clearance

Legacy Pharma Inc. SEZC acquired InterMune, Inc. from Roche Holding AG (SWX:ROG).

Roche Announces FDA Approves Roche’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness

Roche Receives FDA Approval for the First Companion Diagnostic to Identify Patients with HER2-ultralow Metastatic Breast Cancer Eligible for ENHERTU

Roche Holding AG Reports Earnings Guidance for the Year 2025

Roche Announces Executive and Committee Changes

Roche's Itovebi Demonstrates Statically Significant and clinically meaningful Overall Survival Benefit in A Certain Type of HR-Positive Advanced Breast Cancer

Roche Receives FDA Clearance with CLIA Waiver for Cobas® liat Molecular Tests to Diagnose Sexually Transmitted Infections At the Point of Care

Roche Receives FDA Clearance For VENTANA DP 600 Slide Scanner In Digital Pathology

Roche Holding AG to Report Fiscal Year 2024 Results on Jan 30, 2025

Roche's Vabysmo® Prefilled Syringe Approved by European Medicines Agency for Treating Retinal Conditions

New and Updated Data for Columvi and Lunsumio At Ash 2024 Reinforce Their Potential to Improve Outcomes for People with Lymphoma

Five-Year Results Confirm Roche’s Polivy Combination Therapy as New Standard of Care for Previously Untreated Aggressive Lymphoma

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Roche’s Columvi Combination for People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Roche Receives FDA Approval for First Companion Diagnostic to Identify Patients with Biliary Tract Cancer Eligible for Her2-Targeted Treatment with ZIIHERA

Roche to Present New and Encouraging Long-Term Follow-Up Data Across Broad Haematology Portfolio At ASH 2024

Roche Presents New Data At CTAD, Demonstrating Its Growing Momentum in Diagnostics for Alzheimer’s Disease

Roche Announces Positive Topline One-Year Results from the Open-Label, Single-Arm Phase IV ELEVATUM Study Evaluating Vabysmo® (Faricimab) for the Treatment of Diabetic Macular Edema (DME) in People from Racial and Ethnic Groups That Are Often Underrepresented in Clinical Trials